Trial Profile
The PROGRESS Study: Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implants Following Surgical Opening of the Frontal Sinus for Chronic Sinusitis: A Randomized Blinded Controlled Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 May 2021
Price :
$35
*
At a glance
- Drugs Mometasone (Primary)
- Indications Sinusitis
- Focus Registrational; Therapeutic Use
- Acronyms PROGRESS
- Sponsors Intersect ENT
- 20 May 2021 According to an Intersect ENT media release, based on the positive data from the PROPEL Contour cohort of this US clinical study, the company has received CE Mark approval for the companys PROPEL Contour (mometasone furoate) sinus implant enabling sales and distribution in the European Union.
- 02 Nov 2017 Results for the second cohort published in an Intersect ENT media release.
- 02 Nov 2017 According to an Intersect ENT media release, results for the second cohort were published in the Journal of the American Medical Association Otolaryngology Head and Neck Surgery.